Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. It was the first monoclonal anti-CD20 antibody to be approved for medical use in human diseases. It was initially licensed for non-Hodgkin‟s lymphoma and then made available for chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. RTX was also successfully used off-label to treat neuromyelitis optica spectrum disorders, MS, myasthenia gravis, autoimmune encephalitis, autoimmune neuropathies, and myopathies.

 

Attribute
[Chem Name]	Rituximab
[Synonym]	IMMunoglobulinG1,anti-(huManCD20(antigen))(huMan-MouseMonoclonalIDEC-C2B8g1-chain),disulfidewithhuMan-MouseMonoclonalIDEC-C2B8k-chain,diMer;Iggamma-1chainCregion;ImmunoglobulinG1Chemicalbook;Hsdb7455;ImmunoglobulinG1(human-mousemonoclonalidec-C2B8gamma1-chainanti-humanantigencd20),disulfidewithhuman-mousemonoclonalidec-C2B8kappa-chain,dimer;Mabthera;Mabthera;Rituxan
[CAS No.]	174722-31-7
[Formula]	C6416H9874N1688O1987S44
[Molecular]	143859.70

Goods Tag